LNC Therapeutics

LNC Therapeutics is developing gut microbiome-targeted drugs to address obesity and related cardiometabolic diseases. All projects encompass basic research, preclinical studies, and clinical trials. The company is supported by leading venture capital investors, such as Seventure Partners (the microbiome-dedicated vehicle Health for Life Capital) and family offices, while establishing global collaborations with renowned medical experts to ensure the highest standards in innovative drug development. To date, LNC Therapeutics has raised a total of €16.5 million, including €1.5 million in grants from BPI France and the Nouvelle-Aquitaine region, enabling the company to continue its research initiatives and introduce next-generation treatments for obesity and cardiometabolic diseases.